# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001047469-17-003061
Filing Date
2017-04-28
Accepted
2017-04-28 16:48:52
Documents
5
Period of Report
2017-06-21
Effectiveness Date
2017-04-28

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | a2231999zdef14a.htm | DEF 14A | 666187
2 | G111872BGI001.GIF | g111872bgi001.gif | GRAPHIC | 190270
3 | G111872BGI002.GIF | g111872bgi002.gif | GRAPHIC | 175151
4 | G1039423.JPG | g1039423.jpg | GRAPHIC | 16435
5 | G755814.JPG | g755814.jpg | GRAPHIC | 88420
| Complete submission text file | 0001047469-17-003061.txt |  | 1315426

Mailing Address 101 PARK DRIVE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RY
Business Address 101 PARK DRIVE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RY 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 0630
Type: DEF 14A | Act: 34 | File No.: 001-37368 | Film No.: 17796474
SIC: 2836 Biological Products, (No Diagnostic Substances)